Atara Biotherapeutics Receives Nasdaq Delisting Notice for Failing Minimum Market Value Requirement
ATRA sits 25% above its 52-week low of $3.92 on light trading volume (0.1× avg).
Summary
Atara Biotherapeutics received a Nasdaq delisting notice for failing to meet the minimum market value requirement, initiating a 180-day compliance period.
Key Events · Legal and Risk Events · ATRA
-
Nasdaq Delisting Notice Received
The company was notified by Nasdaq that it no longer meets the $50 million minimum market value for listed securities (MVLS) requirement, based on the last 30 consecutive business days.
-
180-Day Compliance Period
Atara Biotherapeutics has until October 27, 2026, to regain compliance by maintaining an MVLS of $50 million or more for a minimum of 10 consecutive business days.
-
Potential Transfer or Delisting
While the notice has no immediate effect on trading, the company may consider transferring to The Nasdaq Capital Market or face delisting if compliance is not achieved by the deadline.
Analysis · ATRA · Life Sciences
Atara Biotherapeutics has received a notice from Nasdaq indicating non-compliance with the $50 million minimum market value for listed securities (MVLS) requirement. This is a critical development, especially given the company's existing 'going concern' warning, previous FDA setbacks, and workforce reductions. While the company has 180 calendar days, until October 27, 2026, to regain compliance, the notice highlights severe financial distress. Failure to meet this requirement could lead to delisting from the Nasdaq Global Select Market, potentially forcing a transfer to a lower tier market or complete removal, further impacting investor confidence and liquidity.
At the time of this filing, ATRA was trading at $4.90 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $41.7M. The 52-week trading range was $3.92 to $19.15. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.